gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · RNAHealthcarePharmaceuticals

Atrium Therapeutics, Inc. Common Stock (RNA)

$8.66−0.69%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$8.55▼ 87.75% in range
Nov 3, 2025Low $7.61 · High $72.93Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

Atrium Therapeutics closed at $8.66 on Nov 4, down 0.69%, 88.1% below its 52-week closing high. Volume of 56.0K shares was 0.22× its 20-day average (below normal).

Split-adjusted performance: +8.4% over one month, -33.8% over six months.

In the quarter ended Jun 30, 2026, revenue was $3M, down 21.9% from a year earlier, with a net margin of -672.0%.

Short interest was 3.7M shares at the Oct 15 settlement, up 9.7% from the prior report (22.9% of float, 12.9 days to cover).

Market cap$148.1M17.1M shares
Revenue · quarter$3.0M−21.9% YoY
Diluted EPS$-1.18—
P/E · TTM—P/S 4.1×
Net margin-672.0%Gross 100.0%
Dividend yieldNone
52-week range7.61 – 72.93−88.1% from high
Volume56.0K0.22× 20-day avg
Volatility · 60d65.8%Annualised
Short % of float22.9%12.9 days to cover
Net cash$263.9MCash $263.9M
Next earnings—Not scheduled
Split-adjusted performance
1W +3.1%1M +8.4%3M −28.5%6M −33.8%YTD −88.0%1Y —3Y +70.1%5Y −60.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum41
Revenue growth28
Net margin26
Value (low P/E)—
Size45

Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short3.7M+9.7% vs prior
Days to cover12.9Settled Oct 15
% of float22.9%
Short vol. 10d39.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
RNAAtrium Therapeutics$8.66−0.69%−33.8%−21.9%−672.0%—$148.1M
MGNXMacroGenics$2.30−1.50%−23.8%+378.0%59.4%—$146.2MCompare
ANTXAN2 Therapeutics$4.17−0.24%−10.3%———$157.4MCompare
CUECue Biopharma$18.92−9.30%−44.3%+166.7%−1943.2%—$137.4MCompare
DERMJourney Medical$4.80+3.45%−7.9%+18.9%−1.7%—$135.5MCompare
PYXSPyxis Oncology$1.62−1.52%−29.8%−100.0%——$134.7MCompare
SIONSionna Therapeutics$3.65−0.14%−91.6%———$164.8MCompare
ZNTLZentalis Pharmaceuticals$1.76−1.40%−58.0%———$166.1MCompare
FHTXFoghorn Therapeutics$2.22+3.99%−52.7%+112.7%−44.7%—$131.5MCompare

News about Atrium Therapeutics

All news →

No recent articles focused on Atrium Therapeutics.

Quick answers

What does Atrium Therapeutics do?
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies.
What is RNA's market cap?
$148.13M, based on the Nov 4 close of $8.66.
Does Atrium Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of RNA is sold short?
3.7M shares, 22.9% of float, as of Oct 15, 2026.
What sector is RNA in?
Healthcare, in the Pharmaceuticals industry.

About Atrium Therapeutics

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

HQ: San Diego, CA391 employeesListed Feb 27, 2026aviditybiosciences.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology